Filters
Among patients with inflammatory arthritis receiving biologic or targeted synthetic disease-modifying anti-rheumatic drugs, those with overweight or obesity face an increased risk of COVID-19 infection, according to a study from Singapore.
Treatment with oral glucocorticoids may contribute to elevated risks of adverse psychiatric outcomes, including the onset and relapse of common psychiatric disorders, as shown in a population-based cohort study.
Women with psoriatic arthritis (PsA) appear to experience increased disease activity, measured either objectively or subjectively, during the perimenopause stage, as shown in a study.
The oral Janus kinase (JAK) inhibitor baricitinib has demonstrated efficacy in inducing and maintaining glucocorticoid-free remission in patients with early polymyalgia rheumatica, according to the phase 3 JAK-Spare trial.
Treatment with secukinumab helps reduce symptoms and disease activity in Chinese children with enthesitis-related arthritis, as shown in a retrospective study.
The use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among adults with obesity and concomitant autoimmune diseases appears to lower the incidence of thromboembolic events, emergency department visits, and mortality, according to a study.
Findings from the phase III RESILIENT study show that a sublingual formulation of cyclobenzaprine (CBP SL) may benefit individuals with fibromyalgia.
Rheumatic and musculoskeletal diseases (RMD) may negatively impact sexual well-being, a study suggests.
New drug applications approved by US FDA as of 1-15 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
A significant proportion of rheumatology patients have been diagnosed with anxiety, depression, or fibromyalgia (FM), reveals a study, noting the importance of including screening for clinical decisions at all routine encounters.
